Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cumberland Pharmaceuticals (CPIX) stocks in Canada

Learn how to easily invest in Cumberland Pharmaceuticals stocks.

Cumberland Pharmaceuticals is a drug manufacturers-specialty & generic business based in the US. Cumberland Pharmaceuticals stocks (CPIX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.86 – a decrease of 7.47% over the previous week. Cumberland Pharmaceuticals employs 83 staff and has a trailing 12-month revenue of around $36 million.

How to buy stocks in Cumberland Pharmaceuticals

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CPIX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cumberland Pharmaceuticals stock price (NASDAQ:CPIX)

Use our graph to track the performance of CPIX stocks over time.

Cumberland Pharmaceuticals shares at a glance

Information last updated 2022-05-12.
Latest market close$2.23
52-week range$2.17 - $7.51
50-day moving average $2.68
200-day moving average $3.15
Wall St. target price$8.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.24

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs

Compare up to 4 providers

Online stock trading

Is it a good time to buy Cumberland Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cumberland Pharmaceuticals price performance over time

Historical closes compared with the close of $2.23 from 2022-05-13

1 week (2022-05-04) N/A
1 month (2022-04-14) -15.21%
3 months (2022-02-11) N/A
6 months (2021-11-15) -17.71%
1 year (2021-05-14) -19.49%
2 years (2020-05-15) -39.40%
3 years (2019-05-15) 5.6
5 years (2017-05-15) 6.36

Is Cumberland Pharmaceuticals under- or over-valued?

Valuing Cumberland Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cumberland Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Cumberland Pharmaceuticals's EBITDA

Cumberland Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $154,811.

The EBITDA is a measure of a Cumberland Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Cumberland Pharmaceuticals financials

Revenue TTM $36 million
Gross profit TTM $27.2 million
Return on assets TTM -5.3%
Return on equity TTM -12.51%
Profit margin -9.75%
Book value $2.90
Market capitalisation $32.8 million

TTM: trailing 12 months

Cumberland Pharmaceuticals share dividends

We're not expecting Cumberland Pharmaceuticals to pay a dividend over the next 12 months.

Have Cumberland Pharmaceuticals's shares ever split?

Cumberland Pharmaceuticals's shares were split on a 2:1 basis on 5 July 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cumberland Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cumberland Pharmaceuticals shares which in turn could have impacted Cumberland Pharmaceuticals's share price.

Cumberland Pharmaceuticals share price volatility

Over the last 12 months, Cumberland Pharmaceuticals's shares have ranged in value from as little as $2.17 up to $7.51. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cumberland Pharmaceuticals's is 0.2029. This would suggest that Cumberland Pharmaceuticals's shares are less volatile than average (for this exchange).

Cumberland Pharmaceuticals overview

Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site